All News

In patients with synchronous metastatic colorectal cancer treated without curative intent, high low-density lipoprotein (LDL) cholesterol was associated with poor survival.

Cure Rare Disease's CRD-002 receives FDA orphan drug designation, advancing hope for SCA3 treatment with innovative oligonucleotide therapy.

With Oregon, Colorado, and New Mexico legalizing psilocybin-assisted therapy, opportunities for treatment are expanding.

The approved injection contains dihydroergotamine (DHE), which is the same medication used in hospitals, in a ready-to-use device.

Explore the latest advancements in RSV vaccination strategies for newborns, focusing on maternal immunization and post-birth protection options.

Logan Schneider, MD, highlights the importance of integrating patient-reported outcomes into clinical trials to better capture the full therapeutic impact of low-sodium oxybate (Xywav) beyond traditional sleep metrics.

The announcement came shortly before updated results from the SURMOUNT-5 clinical trial, which found Zepbound had superior weight-loss effects over Wegovy.

The seasonal surge in skin irritations underscores the ongoing need for effective and convenient remedies.

The data are from the phase 2 iMMagine-1 study.

Emrelis is a groundbreaking treatment for advanced non-small cell lung cancer, targeting high c-Met protein overexpression.

The FDA approved belzutifan, the first oral treatment for pheochromocytoma and paraganglioma, offering a new treatment pathway for patients with these rare tumors.

New trial results reveal icotrokinra's effectiveness in achieving significant skin clearance for challenging scalp and genital psoriasis.

Effectively communicating research findings to patients, health care professionals, and policy payers is necessary for engagement.

Like other high-risk groups, children with sickle cell disease have a heightened risk of invasive pneumococcal disease, even if they receive proper pneumococcal conjugate vaccine coverage.

This new generic will impact both oncology and community pharmacists.

Administration during peak vaccine effectiveness provides maximal protective benefit

FDA and CDC halt Ixchiq chikungunya vaccine for adults 60 years and older due to severe adverse events, including fatalities, urging caution in vaccination practices.

The executive order gives pharmaceutical companies 30 days to voluntarily lower prices.

Despite being an effective treatment option, intravenous immunoglobulin (IVIG) can cause transient adverse events in pediatrics with primary immunodeficiency, including headache and fever.

A natural aging supplement enhances muscle strength and reduces biological age, promoting healthier aging.

Artificial intelligence (AI) can transform rare disease research by leveraging patient data, enhancing evidence generation, and improving communication between patients and health care professionals.

A new multicomponent vaccine, mRNA-1083, shows promise in enhancing immune responses against influenza and COVID-19, addressing vaccine hesitancy effectively.

Explore the latest insights on emerging antibody drug conjugates for HER2 breast cancer and real-world management strategies.